Oncolytics Biotech (TSE:ONC) Trading 24.1% Higher - Still a Buy?

Shares of Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) shot up 24.1% during trading on Wednesday . The company traded as high as C$1.72 and last traded at C$1.70. 892,106 shares were traded during mid-day trading, an increase of 556% from the average session volume of 135,968 shares. The stock had previously closed at C$1.37.

Wall Street Analyst Weigh In

Separately, Jones Trading cut shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th.

Oncolytics Biotech Trading Down 5.3%

The company has a market cap of C$124.09 million, a price-to-earnings ratio of -4.49 and a beta of 1.35. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. The firm's 50-day moving average price is C$0.78 and its 200 day moving average price is C$0.93.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.